Indeed, the reduction of FOXP3+CD4+ Treg cells in tumor tissue after anti-CTLA-4 mAb (Ipilimumab) treatment was strongly associated with clinical benefit (Hodi et al., 2008; Liakou et al., 2008). This evidence concerns the gene FOXP3 and neoplasm.